Fast Locator 2011-2012: Xcelience, LLC - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Xcelience, LLC

Xcelience is a premier provider of formulation development and manufacturing solutions with a solid reputation for accelerating early phase small molecule development. Our outstanding quality record, significant drug development expertise, willingness to customize, and disciplined project management enable us to deliver real advantage to clients with the need to speed potential drugs to clinical trials.

Since 1997, Xcelience has been renowned for reliably expediting drug product development for oral solid, semi-solid and liquid dosage forms. Our formulation development scientists have considerable experience overcoming challenging associated with physical and chemical properties of drug substance, or limited quantities of active pharmaceutical ingredient (API), in a manner that results in compounds with improved solubility and bioavailability. Xcelience operates out of a cGMP compliant, FDA audited, DEA licensed facility in Tampa, Florida.

Xcelience is more than just the market leader for powder-in-capsule services, which enable clients to fill very small amounts of API into capsule and reduce time to first-in-human studies by as much as 45% relative to traditional drug development programs, we are a full spectrum formulation development and manufacturing provider. Our recently expanded process technology capabilities reflect our continued commitment to help clients build towards improved manufacturing outcomes in a manner consistent with the FDA’s Quality by Design initiative.

Regions where services are provided:

North America and Europe

Outsourcing serivces provided:

Development and Phase I/IICTM

  • Solid dose, semisolids, and liquids development
  • Process development-small molecule

Analytical Services

  • Chemistry and stability
  • Particle characterization

Packaging and Logistics

  • Clinical labels
  • Clinical packaging and distribution


Partnering with a specialist like Xcelience for early phase development can reduce product risk and accelerate drug development timelines. For more information, contact Xcelience at 608.643.4444 or visit


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here